Increased Mortality in Schizophrenia Due to Cardiovascular Disease – A Non-Systematic Review of Epidemiology, Possible Causes, and Interventions
Open Access
- 26 September 2014
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 5, 137
Abstract
Background: Schizophrenia is among the major causes of disability worldwide and the mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing concern that this health challenge is not fully understood and efficiently addressed. Methods: Non-systematic review using searches in PubMed on relevant topics as well as selection of references based on the authors experience from clinical work and research in the field. Results: In most countries, the standardized mortality rate (SMR) in schizophrenia is about 2.5, leading to a reduction in life expectancy between 15 and 20 years. A major contributor of the increased mortality is due to CVD, with CVD mortality ranging from 40-50% in most studies. Important causal factors are related to lifestyle, including poor diet, lack of physical activity, smoking and substance abuse. Recent findings suggest that there are overlapping pathophysiology and genetics between schizophrenia and CVD risk factors, further increasing the liability to CVD in schizophrenia. Many pharmacological agents used for treating psychotic disorders have side effects augmenting CVD risk. Although several CVD risk factors can be effectively prevented and treated, the provision of somatic health services to people with schizophrenia seems inadequate. Further, there is a sparseness of studies investigating the effects of life-style interventions in schizophrenia, and there is little knowledge about effective programs targeting physical health in this population. Discussion: The risk for CVD and CVD-related deaths in people with schizophrenia is increased, but the underlying mechanisms are not fully known. Coordinated interventions in different health care settings could probably reduce the risk. There is an urgent need to develop and implement effective programs to increase life expectancy in schizophrenia, and we argue that mental health workers should be more involved in this important task.Keywords
This publication has 194 references indexed in Scilit:
- Randomized double‐blind placebo‐controlled study of leptin administration after gastric bypassObesity, 2013
- Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptomsSchizophrenia Research, 2011
- Reward, dopamine and the control of food intake: implications for obesityTrends in Cognitive Sciences, 2011
- Effect of a Motivational Intervention on Exercise Behavior in Persons with Schizophrenia Spectrum DisordersCommunity Mental Health Journal, 2010
- The role of the insula in schizophreniaSchizophrenia Research, 2010
- Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysisSchizophrenia Research, 2010
- Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)European Psychiatry, 2009
- Influence of antipsychotics on mortality in schizophrenia: Systematic reviewSchizophrenia Research, 2009
- Cardiorespiratory Fitness as a Quantitative Predictor of All-Cause Mortality and Cardiovascular Events in Healthy Men and WomenJAMA, 2009
- A Systematic Review of Mortality in SchizophreniaArchives of General Psychiatry, 2007